A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway

Seiichi Hosaka, Keisuke Horiuchi, Masaki Yoda, Robert Nakayama, Takahide Tohmonda, Michiro Susa, Masaya Nakamura, Kazuhiro Chiba, Yoshiaki Toyama, Hideo Morioka

研究成果: Article査読

28 被引用数 (Scopus)

抄録

Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.

本文言語English
ページ(範囲)1493-1498
ページ数6
ジャーナルJournal of Orthopaedic Research
30
9
DOI
出版ステータスPublished - 2012 9月

ASJC Scopus subject areas

  • 整形外科およびスポーツ医学

フィンガープリント

「A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル